Direct medical costs for stage-specific breast cancer: a retrospective analysis

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2020-03-01 DOI:10.2217/bmt-2019-0014

Q. Alefan, A. Saadeh, R. Yaghan

引用次数: 8

Abstract

Aim: To analyze the direct medical costs of breast cancer (BC) patients in the north of Jordan. Patients: A cohort of BC patients treated during 2015 at King Abdullah University Hospital. Methods: A retrospective analysis of 119 patients, where all records including age, sex, treatment processes and costs were extracted from the patients’ profiles and examined. Results: The mean age of patients was 50.8 (±10.2) years. The total sample cost was Jordanian dinar 1,393,325 (US$1,963,560). The mean cost per patient from stage I to IV was Jordanian dinar 6696, 9183, 11,970 and 15,073, respectively. Medications were the most expensive resource used. Stage IV had the highest cost and largest number of patients. Conclusion: Direct medical costs associated with BC are considerable. Three-quarters of the cost were devoted to medications.

查看原文本刊更多论文

分期乳腺癌的直接医疗费用:回顾性分析

目的:分析约旦北部乳腺癌(BC)患者的直接医疗费用。患者:2015年在阿卜杜拉国王大学医院接受治疗的BC患者队列。方法:对119例患者进行回顾性分析，从患者资料中提取年龄、性别、治疗过程、费用等所有记录进行分析。结果:患者平均年龄50.8(±10.2)岁。样本总费用为约旦第纳尔1,393,325(1,963,560美元)。每名患者从I期到IV期的平均费用分别为约旦第纳尔6696、9183、11970和15073。药物是最昂贵的资源。第四阶段的费用最高，患者人数最多。结论:与BC相关的直接医疗费用相当可观。四分之三的费用花在了药物上。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.